Amendment #145 to H4617

Reporting Technical Corrections

Mr. Cusack of Braintree moves to amend the bill in Section 8, in line 108 by striking out the following words: --

“in the same manner as the assessment pursuant to section 68 of chapter 118E”,

AND in Section 24, in subsection 21, in line 561 by striking out the following words: --

“(3) All biosimilar therapeutic biologics applications (BLA), upon the receipt of an action date from the FDA.”, and inserting in place thereof the following new words: --

“(3) All biosimilar biologics license applications (BLA), upon the receipt of an action date from the FDA.”

AND in Section 34, in lines 666-667, by striking out the following words: --

“same manner as the assessment pursuant to section 68 of chapter 118E”,

AND in Section 35, in line 709, by inserting after the words “management of specialty products lists (3)” the following words: --

“aggregate”